The study is meant to reveal whether a shorter treatment using a new combination of four different antibiotics could be as effective as the regular, longer treatment for tuberculosis (TB).If this research, named SimpliciTB, turns out successful, the treatment period for drug-sensitive tuberculosis could be reduced from six to four months, and the treatment of drug-resistant tuberculosis could go down from 18-24 months to six months.
Shorter treatmentA shorter treatment of TB brings several significant advantages. If the patient is cured faster, the period of contagiousness to others will also be shorter, which will also decrease the chance of the disease spreading. Additionally, it helps increase the patients’ compliance. The access to hospitals and proper medical care in the countries where TB occurs is often limited, which frequently puts the therapy compliance at stake in longer-term treatments. The shorter the treatment, the better the chances are of a patient finishing it. In the case of TB, completing the entire course of treatment is crucial. Mediocre therapy compliance can result in an increased resistance of the bacteria.
Radboud university medical center’s roleThe study is a global initiative of the TB Alliance. The Sub-Saharan African part of the study is carried out by PanACEA, a consortium of 16 institutes in 11 countries, coordinated by Martin Boeree and Rutger Spoor from the department of Pulmonary Diseases at Radboud university medical center. PanACEA received 12 million euros for this study, of which 1.6 million euros is made available to Radboud university medical center. Radboud university medical center takes on the management and medical monitoring and will work on the research capacity development of the African partners.
Capacity developmentThe continued development of African clinical research centers is a priority of the PanACEA consortium. Its aim is to get these centers to a higher level and keep them there and to have their clinical research meet the highest quality requirements, such as those of the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). This will put African centers in a position in which they will be able to lead future research. Aspects of capacity development include the development of infrastructure, admission facilities, laboratories and drugstores, but also the scientific support of PhD candidates and postdocs.
About tuberculosisTuberculosis is a prevalent infectious disease. About 2.3 billion people around the world have a latent infection, and 10 million new patients develop the active disease each year. Tuberculosis is caused by the Mycobacterium tuberculosis bacteria. These bacteria penetrate the cells and can become encased there. During this process, the tissue can get damaged, which leads to the disease. Tuberculosis generally affects the lungs but can also affect other parts of the body.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
With concerted effort, tuberculosis could be eradicated in 30 years time March 24th was World Tuberculosis Day24 March 2022
Since 2020, the number of deaths from tuberculosis increased for the first time in a decade, caused by the COVID pandemic: fewer people had access to the right care on time. Some catching up is needed.read more
HIV drug approved for young children Research on optimal dosing published in The Lancet HIV16 March 2022
For young children with HIV, there is now an effective and safe drug available that inhibits the infection.read more
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development15 July 2021
The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortiumread more
First Dutch professor of infectious disease outbreaks at Radboud university medical center4 June 2021
Chantal Bleeker-Rovers about research on coronavirus, Q fever and other infectious diseases outbreaksread more
Image recognition for population-based lung cancer screening An interview with Bram van Ginneken26 April 2021
Being able to automatically recognize lung tumors on CT scans: professor of functional image analysis Bram van Ginneken developed software within his Vici project that is now used worldwide. The resulting cost savings bring the introduction of a population-based lung cancer screening closer.read more